Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits

Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits

Edwards Lifesciences (NYSE:EW) highlighted new clinical data for its transcatheter tricuspid repair and transcatheter aortic valve replacement programs, including results from the CLASP IITR trial of the PASCAL system and the PROGRESS trial evaluating TAVR in certain patients with moderate aortic st

Edwards Lifesciences says PASCAL beats medical therapy for tricuspid repair

Edwards Lifesciences says its PASCAL tricuspid repair trial beat medical therapy, cutting regurgitation and boosting quality of life. Read more here.

Edwards Says PASCAL Outperformed Medical Therapy on Tricuspid Trial Endpoint

At one year, 80% of PASCAL-treated patients had moderate or lower tricuspid regurgitation, compared with 30% of control patients.

CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System

SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the six-month primary endpoint of the CLASP II TR trial. The evidence further showed significant reduction of tricuspid regurgitation (TR) and substantially improved health status, both sustained through one year. The more...